Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas

By Kelly CloonanShares of Ocugen ticked higher after its treatment for retinitis pigmentosa, or RP, a type of genetic eye disorder, got provisional approval and priority designation from regulators in the Bahamas.The stock was up 2.9% to $1.03 in premarket trading on Friday. At Thursday's market cl…